Q32 Bio Inc
QTTB1.850USD
+0.110+6.32%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
22.57MValor de mercado
PerdaP/L TTM
Mais detalhes de Q32 Bio Inc Empresa
Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.
Informações da empresa
Código da empresaQTTB
Nome da EmpresaQ32 Bio Inc
Data de listagemMar 28, 2018
CEOMs. Jodie Pope Morrison
Número de funcionários42
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 28
Endereço830 Winter Street
CidadeWALTHAM
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02451
Telefone17819990232
Sitehttps://www.q32bio.com/
Código da empresaQTTB
Data de listagemMar 28, 2018
CEOMs. Jodie Pope Morrison
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Detalhamento da receita
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
Monaco asset management S.A.M.
4.85%
Outro
43.90%
Investidores
Investidores
Proporção
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
Monaco asset management S.A.M.
4.85%
Outro
43.90%
Tipos de investidores
Investidores
Proporção
Venture Capital
28.82%
Private Equity
18.47%
Investment Advisor
17.33%
Corporation
5.92%
Hedge Fund
1.98%
Investment Advisor/Hedge Fund
1.76%
Research Firm
1.17%
Individual Investor
0.62%
Outro
23.93%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
211
9.72M
79.73%
-4.89M
2025Q1
223
10.26M
84.16%
-4.38M
2024Q4
223
11.35M
93.20%
-1.04M
2024Q3
208
11.60M
102.62%
+2.77M
2024Q2
197
10.02M
90.20%
+1.83M
2024Q1
230
9.37M
85.14%
+7.24M
2023Q4
242
1.68M
52.16%
-377.72K
2023Q3
262
1.62M
50.50%
-460.61K
2023Q2
275
1.63M
50.84%
-543.11K
2023Q1
291
1.72M
53.55%
-518.81K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
OrbiMed Advisors, LLC
2.25M
18.47%
--
--
Mar 31, 2025
Atlas Venture
2.09M
17.15%
--
--
Mar 31, 2025
Abingworth Management Limited
1.10M
9.04%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
803.42K
6.59%
--
--
Mar 31, 2025
Monaco asset management S.A.M.
505.45K
4.14%
-69.36K
-12.07%
Mar 31, 2025
ARCH Venture Partners
320.48K
2.63%
--
--
Mar 31, 2025
Pfizer Inc
277.78K
2.28%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
309.21K
2.54%
-7.36K
-2.32%
Mar 31, 2025
Sanofi SA
244.08K
2%
--
--
Mar 31, 2025
Bristol Myers Squibb
200.24K
1.64%
-558.90K
-73.62%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Data
Tipo
Proporção
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
